Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/6/2008

ting results, our 2006 financial statements also reflect the acquisition of Miikana Therapeutics and the resultant $29.5 million non- cash charge booked as acquired in-process R&D. In 2008, we expect our cash expenses will remain at similar levels as compared to 2007 or increase slightly as a result of supporting ongoing and new clinical trials."

James S. Burns, President and Chief Executive Officer further commented, "These are volatile times in the financial markets and microcap oncology companies such as ours have been hit particularly hard. We are financed adequately and have sufficient cash to fund our clinical and research programs well into 2009. We will continue to pursue a strategy focused on orally- administered, small molecule compounds that can provide us with multiple opportunities to succeed and to mitigate the inherent risk of oncology drug development."

The fourth quarter update call is scheduled for Thursday, March 13, 2008 at 10:00 a.m. ET and will include a question and answer session. To access the live conference, please dial 800-418-7236 (U.S. or Canada) or 973-935-8757 (internationally) and reference conference number 37155333 at least 10 minutes prior to the beginning of the call. A digital recording will be available approximately two hours after completion of the conference and will be accessible for 60 days. To access the recording, dial 800-642-1687 (U.S. or Canada) or 706-645-9291 (internationally) and enter the digital pin number 37155333. This call will not be web cast; however, an audio replay will also be available on the Company's website at http://www.entremed.com approximately one hour after the conclusion of the live conference.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for canc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced ... at The American Society of Hematology 51st Annual Meeting ... presented on the clinical results from the Phase 1 ... pharmacokinetic/pharmacodynamic (PK/PD) profile in dose levels ranging from 100 ...
(Date:12/2/2009)... China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" ... a leading pharmaceutical company,specializing in the development, manufacturing, ... China, today announced that 105 of,its drugs have ... which was issued by China,s Ministry of Human ...
(Date:12/2/2009)... -- The world is going through,extraordinary times; markets are ... industries. It turns out that the pharma industry has ... take a,vacation. , During the ... Johnson & Johnson inaugurated an R&D center in Shanghai, ...
(Date:12/2/2009)... to the National Institute of Health, 40 percent to 45 ... of diabetic retinopathy. Diabetic retinopathy, damage to the retina ... blindness in people with diabetes and is one of the ... percent of all patients who,ve had diabetes for 10 years ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
... Support R&D Efforts and Clinical Trials Advancing,the BiTE ... Micromet, Inc.,(Nasdaq: MITI ) ("Micromet" or ... for the treatment of cancer,inflammation and autoimmune diseases, ... agreement with various institutional investors to raise,$40 million ...
... 19 - 22,2008, the fairgrounds in Dusseldorf, Germany ... - World Forum for Medicine. As the,leading international ... will,feature about 4,300 exhibitors, two major congresses, an ... at MEDICA 2008 will include the latest products ...
... BOSTON, Sept. 30 Solos Endoscopy, Inc. (Pink,Sheets: ... intends to expand,their current industry to include and ... by implementing a business,strategy. The Company,s strategy is ... its customer base., Solos Endoscopy expects continuous ...
Other Biology Technology:Micromet Announces Definitive Agreement for $40 Million Private Equity Placement 2Micromet Announces Definitive Agreement for $40 Million Private Equity Placement 3Micromet Announces Definitive Agreement for $40 Million Private Equity Placement 4MEDICA 2008 Returns in November 2Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market 2
(Date:12/3/2009)... 3, 2009) Van Andel Research Institute (VARI) ... (ABA) works at the molecular level to help plants respond ... findings, published in the journal Nature , could help ... and combat global food shortages. The findings could also ...
(Date:12/3/2009)... the past three years in the troposphere (lower atmosphere) ... results, which are the first of their kind in ... between 2002 and 2005. , Over recent years, physicists ... carbon dioxide (CO2) levels, and how these have evolved ...
(Date:12/2/2009)... cigarette smoke have an increased risk of developing lung cancer ... of this study are published in Cancer Epidemiology, Biomarkers ... Cancer Research, as part of a special tobacco focus in ... 219,000 Americans will be diagnosed with lung cancer; more than ...
Breaking Biology News(10 mins):VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3CO2 levels rising in troposphere over rural areas 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Procter 26 Gamble Pharmaceuticals Launches Asacol 28R 29 HD 28mesalamine 29 Delayed Release Tablets 4692 1Procter 26 Gamble Pharmaceuticals Launches Asacol 28R 29 HD 28mesalamine 29 Delayed Release Tablets 4692 2Procter 26 Gamble Pharmaceuticals Launches Asacol 28R 29 HD 28mesalamine 29 Delayed Release Tablets 4692 3Procter 26 Gamble Pharmaceuticals Launches Asacol 28R 29 HD 28mesalamine 29 Delayed Release Tablets 4692 4Procter 26 Gamble Pharmaceuticals Launches Asacol 28R 29 HD 28mesalamine 29 Delayed Release Tablets 4692 5Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 1Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 2Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 3Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 4Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 5Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet 4690 6Mixed Marks for Swine Flu Updates 50875 1Mixed Marks for Swine Flu Updates 50875 2
... DALLAS July 6, 2008 Tiny strands of genetic material ... as major players in gene regulation, the process inside cells that ... to fight disease. , The idea that RNA (ribonucleic acid) ... it has been unclear how RNA strands might regulate the process. ...
... Diversity among the ancestors of such marine creatures as ... rise beginning 144 million years ago with no clear ... This contradicts previous work showing dramatic increases beginning 248 ... diversity., "Some of the time periods in the past ...
... Mass., July 3, 2008 -- Sirtris, a GlaxoSmithKline company ... treat diseases of aging such as Type 2 Diabetes, ... today,s online edition of Cell Metabolism that ... showed an overall health improvement, including improved bone health, ...
Other Biology News:UT Southwestern researchers identify new targets for RNAs that regulate genes 2UT Southwestern researchers identify new targets for RNAs that regulate genes 3Ancient marine invertebrate diversity less explosive than thought 2Ancient marine invertebrate diversity less explosive than thought 3Long-term study of middle-aged mice shows 2Long-term study of middle-aged mice shows 3
...
... autofluorescent pigment lipofuscin accumulates in the ... neurons. The presence of lipofuscin granules ... microscopy in the central nervous system ... emission spectra, which overlaps with those ...
Purified anti-LAT...
Polyclonal Antibody to AHI1 / Jouberin...
Biology Products: